# GLP-1 and SGLT2 Use From 2017 to 2023: Who Was Left Out as Use Rose Tenfold

National survey data from 2017-2023 show GLP-1 and SGLT2 use rising tenfold as per-prescription spending rose nearly 50%, with uninsured adults at 0.53 times the odds of use.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/who-the-price-filtered-out
Updated: 2026-11-14
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 and SGLT2 Use From 2017 to 2023: Who Was Left Out as Use Rose Tenfold

Use of GLP-1 drugs and SGLT2 inhibitors rose from 0.42% to 4.45% of adults between 2017 and 2023, while per-prescription spending rose nearly 50%. Uninsured adults had 0.53 times the odds of use.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20267 min readUpdated November 2026

Adjusted odds of use by group · parity (1.0) · uninsured · 0.53 · low education · 0.67 · low income · 0.73 · Hispanic adults · 0.74 · Black adults · 0.78

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   Between 2017 and 2023, use of GLP-1 drugs and SGLT2 inhibitors rose from 0.42% to 4.45% of adults, and from 8.50% to 31.36% among adults with an approved indication.
-   Over the same stretch, per-prescription spending rose by nearly 50%.
-   Uninsured adults had 0.53 times the odds of using one (95% CI 0.31-0.92). Lower odds also appeared for Black and Hispanic adults, lower-income earners and those with less education.
-   Off-label use fell from 27% to 12%.

The [GLP-1 monthly cost guide](https://buythisglp.com/research/how-much-does-a-glp1-cost-per-month) describes the prices patients may encounter. A separate analysis of seven years of the Medical Expenditure Panel Survey looked at who received treatment as use grew [\[1\]](https://buythisglp.com/research/who-the-price-filtered-out#ref-1). Overall use rose from 0.42% to 4.45% of adults. Among adults with a condition for which the drugs are approved, it rose from 8.50% to 31.36%.

For someone who has insurance and receives a denial, the [Wegovy appeal guide](https://buythisglp.com/research/wegovy-insurance-denied-appeal) explains where to find the plan’s reason and how to respond. Spending per prescription rose by nearly half over the same period. The survey analysis measured use and spending. It cannot establish whether rising prices caused the differences in use across groups.

Compared with privately insured adults, uninsured adults had lower adjusted odds of using either drug class (OR 0.53, 95% CI 0.31–0.92). The study also reported lower odds for middle- and lower-income adults compared with higher-income adults, and for Black and Hispanic adults compared with White adults. These estimates use a separate reference category for each characteristic.

How the survey classified off-label use

The share fell from 27% to 12%. The researchers classified prescriptions by whether they could link them to an approved indication in the survey records.

One measurement caveat carries through everything above. The study reports GLP-1 drugs and SGLT2 inhibitors as a single utilization outcome, so none of these odds ratios is a GLP-1 figure on its own, and the two classes have different prices, different indications and different coverage rules. The direction is clear and the attribution to one class is not available.

The [GLP-1 insurance coverage guide](https://buythisglp.com/research/does-insurance-cover-glp1) explains how coverage rules can affect out-of-pocket costs. If you get insurance through work, the [employer coverage guide](https://buythisglp.com/research/does-your-employer-cover-a-glp1) explains what to ask your benefits team. The study above combines two drug classes and does not estimate access through any specific employer plan.

## Frequently asked

How did use differ by insurance status?

Uninsured adults had 0.53 times the adjusted odds of using either drug class compared with privately insured adults. Lower odds also appeared for adults with less education, for middle- and low-income earners, and for Black and Hispanic adults.

Are these drugs mostly used off-label?

Not according to this data. Off-label use fell from 27% to 12% between 2017 and 2023, while overall use rose about tenfold.

Do these figures describe GLP-1 drugs specifically?

No. The study combines GLP-1 receptor agonists and SGLT2 inhibitors into one utilization measure, so the disparities cannot be attributed to either class on its own.

## Sources

1.  \[1\] Jacobs M, Fang Q, Ellis C (2026). Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017-2023: Demographic, Income, and Insurance Associations Journal of General Internal Medicine. [PMID 41984414](https://pubmed.ncbi.nlm.nih.gov/41984414/)

## Where to get it

### The cheapest GLP-1

Every seller that publishes a price, ordered lowest first on the standing month-to-month rate, plus the question to ask before you pay any of them.

[See the board →](https://buythisglp.com/best/cheapest-glp1)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
